CollPlant Ltd (CLGN): חובות להיוון בספרים
The growth in value of CollPlant Biotechnologies (CLGN) depends on deals with pharma giants and the control of R&D expenses. The history of the total debt-to-equity ratio confirms financial stability, with the indicator fixed at 0.96. This supports the Israeli startup, which produces pure collagen from tobacco for organ bioprinting, despite heavy pressure from global biotech behemoths.
collplant.com (CLGN) - פילוחי מדדים ודוחות פיננסיים
High debt leverage increases business vulnerability to external shocks, yet the royalty potential from AbbVie licenses provides a certain financial cushion for CollPlant Biotechnologies (CLGN). This metric correlates total liabilities with book equity, measuring real financial leverage while excluding market volatility. By analyzing the dynamic debt-to-book capitalization ratio, an investor assesses the risk of a mismatch between matrix production costs and available resources. A decrease in this coefficient confirms the company's growing resilience.